Get detailed information on Abemaciclib, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...
Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the ...
Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key bre ...
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...
Atossa Therapeutics has strong financials with $79.5 million in cash and a cash runway of 13-14 quarters, minimizing ...
News Medical on MSN6d
Key kinase involved in cell division linked to abnormal blood vessel growth in genetic disorderInhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...
Tango Therapeutics (TNGX) announced an update on its PRMT5 program. Based on data from the dose escalation and early dose expansion cohorts of ...
Six/UW/Seattle Children’s Cancer Consortium scientists received new funding from the Breast Cancer Research Foundation to ...
CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib, which help slow cancer cell division. Immunotherapy: For some patients with triple-negative breast cancer (which lacks hormone receptors ...
On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback